EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Creatinine-to-Cystatin C Ratio Combined with FIB-4 and ELF for Noninvasive Fibrosis Assessment in MASLD

Masafumi Oyama, Tadashi Namisaki iD, Akihiko Shibamoto, Satoshi Iwai iD, Masayoshi Takami, Yuki Tsuji, Yukihisa Fujinaga iD, Hiroaki Takaya, Takashi Inoue, Norihisa Nishimura iD, Shinya Sato iD, Koh Kitagawa iD und 6 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26199560 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Masafumi Oyama und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Liver Cirrhosis, Creatinine, Cystatin C. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, Grant-in-Aid for Research on Hepatitis from the Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The creatinine-to-cystatin C ratio (CCR), a surrogate for skeletal muscle mass, may also be associated with liver fibrosis due to the strong link between sarcopenia and liver disease progression. We aimed to evaluate the utility of CCR as a noninvasive marker of liver fibrosis in metabolic-dysfunction-associated steatotic liver disease (MASLD). This retrospective study included 104 patients with biopsy-proven MASLD. CCR was calculated using serum creatinine and cystatin C levels. Liver fibrosis was staged histologically (F0–F4), and skeletal muscle mass was assessed using the skeletal muscle index (SMI) on computed tomography. Associations between CCR and liver fibrosis, SMI, and nonalcoholic fatty liver disease activity score were analyzed. ROC analysis evaluated CCR performance alone and in combination with FIB-4 and enhanced liver fibrosis (ELF) scores. CCR values were significantly lower in patients with significant fibrosis (≥F2). The AUROC of CCR for detecting ≥F2 fibrosis was 0.621 (95% CI: 0.509–0.733), with an optimal cutoff of 0.664. CCR alone yielded an AUC of 0.815 for predicting ≥F2 fibrosis. Combining CCR with FIB-4 and ELF substantially improved diagnostic accuracy, increasing the AUROC from 0.621 (CCR alone) to 0.820 for the combined model. CCR correlated positively with SMI (r = 0.451, p < 0.001). CCR is a simple, cost-effective biomarker reflecting muscle mass and liver fibrosis in MASLD. Combining CCR with established markers may enhance risk stratification and reduce the need for liver biopsy in selected cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseLiver CirrhosisCreatinineCystatin CSarcopeniaRetrospective StudiesBiomarkersDisease ProgressionROC CurveMuscle, SkeletalTomography, X-Ray ComputedHumansMaleFemaleAdultMiddle AgedAgedLiverBiopsy

Stichwörter der Autor:innen

MASLDliver fibrosisnon-invasive toolthe creatinine-to-cystatin C ratio

Substanzen

CreatinineCystatin CBiomarkers

Autor:innen und Institutionen

  • Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
  • Department of Evidence-Based Medicine, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan.
  • Clinical Research Center, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan.

ORCID-Profile: Tadashi Namisaki, Satoshi Iwai, Yukihisa Fujinaga, Norihisa Nishimura, Shinya Sato, Koh Kitagawa, Akira Mitoro, Kiyoshi Asada, Junichi Hanatani

Förderung

  • JSPS KAKENHI
  • Grant-in-Aid for Research on Hepatitis from the Japan Agency for Medical Research and Development

Zitieren

APA

Oyama, M., Namisaki, T., Shibamoto, A., Iwai, S., Takami, M., Tsuji, Y., Fujinaga, Y., Takaya, H., Inoue, T., Nishimura, N., Sato, S., Kitagawa, K., Kaji, K., Mitoro, A., Asada, K., Masuda, H., Hanatani, J., & Yoshiji, H. (2025). Creatinine-to-Cystatin C Ratio Combined with FIB-4 and ELF for Noninvasive Fibrosis Assessment in MASLD. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199560

Vancouver

Oyama M, Namisaki T, Shibamoto A, Iwai S, Takami M, Tsuji Y, et al. Creatinine-to-Cystatin C Ratio Combined with FIB-4 and ELF for Noninvasive Fibrosis Assessment in MASLD. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199560

BibTeX
@article{Oyama2025,
  author = {Oyama, Masafumi and Namisaki, Tadashi and Shibamoto, Akihiko and Iwai, Satoshi and Takami, Masayoshi and Tsuji, Yuki and Fujinaga, Yukihisa and Takaya, Hiroaki and Inoue, Takashi and Nishimura, Norihisa and Sato, Shinya and Kitagawa, Koh and Kaji, Kosuke and Mitoro, Akira and Asada, Kiyoshi and Masuda, Hiroyuki and Hanatani, Junichi and Yoshiji, Hitoshi},
  title = {Creatinine-to-Cystatin C Ratio Combined with FIB-4 and ELF for Noninvasive Fibrosis Assessment in MASLD},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26199560}
}
Kostenlos starten →